Random good picture Not show

(31) We measured the plasminogen(PLG)content and plasmin(PL)activity in 54 leukemic patients.

(32) PURPOSE : To establish a stable cell strain secreted recombinant tissue - type plasminogen activator ( rt - PA ).

(33) Recombinant tissue-type plasminogen activator (r-TPA) was also used when clinically indicated.

(34) This review will focus on approved agents and the clinical trials that have led to their widespread use, including streptokinase, urokinase, recombinant tissue-type plasminogen activator.

(35) Plasma levels of prekallikrein (PK), plasminogen (PLG), fibrinogen (FIG) in 84 cases of malignant tumor were studied with an advanced method. Each item was measured 100 times.

(36) Objective To investigate the anticoagulative and fibrinolytic effects of lumbrokinase and their relation to tissue plasminogen activator (t-PA).

(37) The properties, determination of plasmin plus plasminogen and the effect on cheese and UHT milk are introduced in this paper.

(38) Objective: To evaluate the efficacy and safety of recombinant tissue plasminogen activator in hyper acute cerebral infarction.

(39) Objective To monitor the dynamic changes of tissue type plasminogen activator(t-PA) and plasminogen activator inhibitor-I(PAI-I) activity after and before PTCA in patients with ACS.

(40) This was accompanied by severe disruption of the blood–brain barrier and an increased rate of intracerebral hemorrhages after tissue plasminogen activator treatment.

(41) AIM: To observe the effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1(PAI-1)and thromboxane B2(TXB-2)in type 2 diabetes mellitus(DM).

(42) In this process, urokinase - type plasminogen activator ( uPA ) and P - selectin play a very important role.

(43) Objective: To identify of urokinase - type plasminogen activator ( UPA ) expression in patients with epithelial ovarian carcinoma.

(44) Intravenous administration of recombinant tissue plasminogen activator remains the most beneficial proven intervention for emergency treatment of stroke.

(45) Objective To explore the relationship between the activity change of tissue type plasminogen activator(TPA) of retinas and retinal edema in retinal ischemia and reperfusion rats.

(46) Should the patients with middlecerebralarteryocclusion of transient ischemic attack be treated with intravenous tissue plasminogen activator?

(47) Plasmin and plasminogen is a major pair of alkaline proteinase in milk, which affects dairy products by hydrolyzing milk proteins.

(48) Refer to the fibrin plate assay and the clot lysis assay for determining the activities of streptokinase and urokinase, we established an assay for the activity determination of plasminogen.

(49) The high-phenol group also experienced a greater drop in the activity of another clot promoter, plasminogen activator inhibitor-1.

(50) Objective To observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.

(51) Objective:To examine whether VLDL or LDL can stimulate the secretion of plasminogen activator inhibitor type 1 (PAI-1) in hepatic cells.

(52) The von Willebrand's disease factors in plasm, adjusted protein of thrombase and inhibitor 1 of activator of plasminogen were detected with enzyme-linked immunosorbent assay.

(52) Sentencedict.com is a sentence dictionary, on which you can find good sentences for a large number of words.

(53) The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.

(54) According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).

(55) The plasminogen activator (PA) system, which controls the formation and activity of plasmin, plays a key role in modulating hemostasis, thrombosis, and several other biological processes.

(56) Objective To study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.

(57) Objective To explore the relationship between plasminogen activator inhibitor type-1 (PAI-1)and its biological behaviour of hepatocellular carcinoma (HCC).

(58) Objective: To identify the significance of urokinase-type plasminogen activator expression in patients with epithelial ovarian carcinoma.

(59) The screening of human tissue plasminogen activator recombinant plasmid showed that the two methods can recognize the positive colones quickly and correctly.